Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript
Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript
Seeking Alpha8/14/2026Neutral
LTRN
Lantern Pharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$33.24M
P/E Ratio
—
EPS
$-1.58
Beta
2.33
52W High
$4.70
52W Low
$1.11
50-Day MA
$3.31
200-Day MA
$3.03
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Lantern Pharma Inc
Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. The company is headquartered in Dallas, Texas.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-16.59M |
| Operating Margin | 0.00% |
| Return on Equity | -157.40% |
| Return on Assets | -73.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.31 |
| Price-to-Book | 9.74 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $12.78M |
| Float | $8.70M |
| % Insiders | 20.32% |
| % Institutions | 24.91% |
Historical Volatility
HV 10-Day
43.74%
HV 20-Day
49.76%
HV 30-Day
80.75%
HV 60-Day
78.47%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($17.50 target)
2
BuyLatest News
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update.
Business Wire8/14/2026Neutral
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET.
Business Wire8/7/2026Neutral
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
DALLAS--(BUSINESS WIRE)--Open Medicine AI is launched as separate entity by Lantern Pharma.
Business Wire8/3/2026Neutral
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
DALLAS--(BUSINESS WIRE)--EMA Phase 1b/2 Clinical Trial for LP-184.
Business Wire7/28/2026Neutral
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop targeted cancer therapies, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers." The allowed claims cover methods of selecting and treating patients with ovar.
Business Wire7/23/2026Neutral
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its multi-agentic AI co-scientist platform, withZeta.ai. ZetaOmics introduces an autonomous “Computational Biologist” persona (agent) that performs real, end-to-end bioinformatics and multi-omic analysis — across any cancer type, and is purpose-built for the rare and pediatric cancers that have long been.
Business Wire7/8/2026Neutral
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
DALLAS--(BUSINESS WIRE)--Harmonic Presentation in form of 8K.
Business Wire6/2/2026Neutral
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received a successful response to its recent Type C meeting request from the U.S. Food and Drug Administration (FDA), focused on the ongoing Phase 2 HARMONIC™ trial of LP-300 in never-smokers with advanced non-small cell lung cancer (NSCLC) adenocarcinoma. In its written responses to Lantern's Type C meeting request, the FDA raised no objections to key.
Business Wire5/19/2026Neutral
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates.
Business Wire5/15/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LTRN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026